Maren Foundation is located in East Hampton, NY. The organization was established in 2016. According to its NTEE Classification (H80) the organization is classified as: Specifically Named Diseases Research, under the broad grouping of Medical Research and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Maren Foundation is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Maren Foundation generated $39.4k in total revenue. This represents a relatively dramatic decline in revenue. Over the past 4 years, the organization has seen revenues fall by an average of (45.1%) each year. All expenses for the organization totaled $137.9k during the year ending 12/2021. You can explore the organizations financials more deeply in the financial statements section below.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Robert Shuhy Sr Trustee | 7 | $0 | |
Thomas Snyder Chairman/trustee | 3 | $0 |
Statement of Revenue | |
---|---|
Contributions, Gifts, Grants & Similar | $0 |
Interest on Savings | $0 |
Dividends & Interest | $7,820 |
Net Rental Income | $0 |
Net Gain on Sale of Assets | $31,559 |
Capital Gain Net Income | $31,559 |
Net ST Capital Gain | $0 |
Income Modifications | $0 |
Profit on Inventory Sales | $0 |
Other Income | $0 |
Total Revenue | $39,379 |
Statement of Expenses | |
---|---|
Compensation of officers, directors, trustees, etc | $56,426 |
Other employee salaries and wages | $0 |
Pension plans, employee benefits | $0 |
Interest | $0 |
Taxes | $5,216 |
Depreciation | $0 |
Occupancy | $23,078 |
Travel, conferences, and meetings | $8,815 |
Printing and publications | $0 |
Other expenses | $13,956 |
Total operating and administrative expenses | $117,860 |
Contributions, gifts, grants paid | $20,000 |
Total expenses and disbursements | $137,860 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $9,591 |
Savings and temporary cash investments | $0 |
Net Accounts receivable | $0 |
Net Pledges Receivable | $0 |
Grants receivable | $0 |
Receivables from Officers, Directors, or Controlling Persons | $0 |
Net other notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $0 |
Net Investments - land, buildings, equipment | $0 |
Investments—mortgage loans | $0 |
Investments—other | $0 |
Net Land, buildings, and equipment | $0 |
Other assets | $315,138 |
Total assets | $324,729 |
Accounts payable and accrued expenses | $0 |
Grants payable | $0 |
Deferred revenue | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Mortgages and other notes payable | $0 |
Other liabilities | $0 |
Total liabilities | $0 |
Over the last fiscal year, Maren Foundation has awarded $90,000 in support to 2 organizations.
Grant Recipient | Amount |
---|---|
JOHNS HOPKINS UNIVERSITY DEPARTMENT OF MEDICINE PURPOSE: THE ONGOING RESEARCH INVESTIGATES WHETHER VITAMIN D REPLACEMENT:1)HELPS REDUCE RISK FACTORS FOR CARDIOVASCULAR DISEASE, NAMELY HYPERTENSION AND HIGH CHOLESTEROL.2)REDUCES BLOOD CLOTS, SUCH AS STROKE AND DEEP VEIN THROMBOSIS.THE HOPKINS LUPUS COHORT IS A THIRTY YEAR LONGITUDINAL COHORT IN WHICH PATIENTS ARE FOLLOWED BY PROTOCOL EVERY THREE MONTHS, WITH OVER 80,000 CLINICAL VISITS FROM MORE THAN 2600 INDIVIDUAL PATIENTS IN THE COHORT DATABASE.THIS QUANTITY OF DATA MAKES IT POSSIBLE IDENTIFY RISK FACTORS FOR OUTCOMES, SUCH AS CARDIOVASCULAR EVENTS AND THROMBOSIS (BLOOD CLOTS) AND TO TEASE OUT THE RELATIVE IMPORTANCE OF DISEASE ACTIVITY, EXPOSURE TO CORTICOSTEROIDS, AND LOW VITAMIN D AS RISK FACTORS FOR THESE EVENTS. THE RESEARCH RESULTS WOULD HELP LUPUS BECAUSE VITAMIN D WOULD REDUCE POTENTIALLY TWO OF THE THREE MAIN RISK FACTORS (LUPUS ACTIVITY AND TRADITIONAL CARDIOVASCULAR RISK FACTORS)THAT CONTRIBUTE TO THE EXCESS RISK OF CARDIOVASCULAR DISEASE IN SLE. | $50,000 |
UNIVERSITY OF MUNSTER PURPOSE: TO STUDY THE INFLUENCE OF DIETARY RESISTANT STARCH CONTENT ON THE GUT MICROBIOTA OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME. RESULTS AVAILABLE UPON REQUEST. | $40,000 |
Organization Name | Assets | Revenue |
---|---|---|
Global Alliance For Tb Drug Development Inc New York, NY | $187,560,796 | $58,653,379 |
Als Therapy Development Foundation Inc Watertown, MA | $19,047,011 | $12,370,651 |
Jeffrey Modell Foundation Inc New York, NY | $36,072,018 | $6,146,213 |
Rothberg Institute Inc Guilford, CT | $0 | $50,949 |
Silent Spring Institute Inc Newton, MA | $4,846,950 | $4,731,717 |
Lupus Clinical Trials Consortium Katherine M Snider President Garden City, NY | $502,663 | $1,883,684 |
Amyloidosis Research Consortium Inc Newton, MA | $2,350,923 | $1,647,972 |
Northeast Als Consortium Inc Boston, MA | $897,067 | $886,426 |
Angel Fund Inc Wakefield, MA | $2,272,939 | $566,086 |
Aurum Institute Usa New York, NY | $145,199 | $368,316 |
Alcohol Research Documentaion Inc Piscataway, NJ | $984,278 | $375,335 |
Acne Cure Alliance Inc Morristown, NJ | $193,415 | $438,873 |